Hematopoietic cell-derived interferon controls viral replication and virus-induced disease by Lang, P A et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Hematopoietic cell-derived interferon controls viral replication
and virus-induced disease
Lang, P A; Cervantes-Barragan, L; Verschoor, A; Navarini, A A; Recher, M;
Pellegrini, M; Flatz, L; Bergthaler, A; Honda, K; Ludewig, B; Ohashi, P S; Lang, K S
Lang, P A; Cervantes-Barragan, L; Verschoor, A; Navarini, A A; Recher, M; Pellegrini, M; Flatz, L; Bergthaler, A;
Honda, K; Ludewig, B; Ohashi, P S; Lang, K S (2009). Hematopoietic cell-derived interferon controls viral
replication and virus-induced disease. Blood, 113(5):1045-1052.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Blood 2009, 113(5):1045-1052.
Lang, P A; Cervantes-Barragan, L; Verschoor, A; Navarini, A A; Recher, M; Pellegrini, M; Flatz, L; Bergthaler, A;
Honda, K; Ludewig, B; Ohashi, P S; Lang, K S (2009). Hematopoietic cell-derived interferon controls viral
replication and virus-induced disease. Blood, 113(5):1045-1052.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Blood 2009, 113(5):1045-1052.
Hematopoietic cell-derived interferon controls viral replication
and virus-induced disease
Abstract
Type I interferon (IFN-I) strongly inhibits viral replication and is a crucial factor in controlling virus
infections and diseases. Cellular activation through pattern recognition receptors induces interferon
production in a wide variety of hematopoietic and nonhematopoietic cell types, including dendritic cells,
fibroblasts, hepatocytes, and cells of neuronal origin. The relative contribution of hematopoietic and
nonhematopoietic cells to the overall interferon response is an important issue which has not been fully
addressed. Using irf7(-/-) and wild-type bone marrow chimeras we analyzed the contribution of IFN-I
from bone marrow-derived sources in the control of viral infections and immunopathology in mice. We
found that during systemic cytopathic virus infection, hematopoietic cells were essential for production
of IFN-I, inhibition of viral spread to peripheral organs, and limiting cell damage. In a model of
autoimmune diabetes induced by noncytopathic virus infection, hematopoietic cell-derived IFN-I was
essential for CD8(+) T cell-dependent cytotoxicity in pancreatic beta-islet cells and induction of
diabetes. These data suggest that during systemic viral infection primarily hematopoietic cell-derived
IFN-I controls viral replication and viral-induced disease.
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Type I interferon (IFN-I) strongly inhibits viral
replication and is a crucial factor in control-
ling virus infections and diseases. Cellular
activation throughpattern recognitionrecep-
tors induces interferon production in a wide
variety of hematopoietic and nonhematopoi-
eticcell types, includingdendriticcells,fibro-
blasts, hepatocytes, and cells of neuronal
origin. The relative contribution of hemato-
poietic and nonhematopoietic cells to the
overall interferon response is an important
issue which has not been fully addressed.
Using irf7/ and wild-type bone marrow
chimeras we analyzed the contribution of
IFN-I from bone marrow–derived sources in
the control of viral infections and immunopa-
thology in mice. We found that during sys-
temic cytopathic virus infection, hematopoi-
etic cells were essential for production of
IFN-I, inhibition of viral spread to peripheral
organs, and limiting cell damage. In a model
of autoimmune diabetes induced by non-
cytopathic virus infection, hematopoietic
cell–derived IFN-I was essential for CD8
T cell–dependent cytotoxicity in pancreatic
-islet cells and induction of diabetes.
These data suggest that during systemic
viral infection primarily hematopoietic cell–
derived IFN-I controls viral replication and
viral-induced disease. (Blood. 2009;113:
1045-1052)
Introduction
Interferon is a polypeptide which has strong antiviral capacity.1-3
Mice lacking the type I interferon (IFN-I) receptor are unable to
limit widespread dissemination of several mouse pathogenic
viruses,4 which highlights the antiviral activity in vivo. Interfer-
ons are produced by a wide variety of cell types that are capable
of responding to specific microbial elements (eg, double- and
single-stranded RNA or DNA of viral origin) via pattern
recognition receptors (PRRs). Some PRRs are widely expressed,
whereas others are limited to specific cell populations. For
instance, RIG-I,5,6 TLR3,7-9 and TLR910-13 induce IFN-I in a
wide variety of hematopoietic and nonhematopoietic cell types
as diverse as macrophages, fibroblasts,14,15 endothelial cells,
hepatocytes,16-18 microglia, and even neurons.19 In contrast,
interferon-inducing Toll-like receptor 7 (TLR7) has only been
reported on murine bone marrow (BM)–derived plasmacytoid
dendritic cells.20,21 Two main pathways have been characterized
to induce IFN-I production: one through cytoplasmic PRRs,
mainly the helicases RIG-I or MDA-5,5 and the second through
transmembrane PRRs, namely TLR3, TLR4, TLR7, and
TLR9.22-25 After virus recognition by the cytosolic PRRs or
TLRs, Tank-binding kinase 1 (TBK1) is activated and induces
phosphorylation of the transcription factors IRF3 and IRF7,
which form homo- and heterodimers, and migrate into the
nucleus.26,27 IRF3 homodimers induce IFN- production, but
are not essential. In contrast, IRF7 (homo- and heterodimers
with IRF3) is essential for the production of IFN- via both
cytosolic and transmembrane PRR pathways.23 While irf3/
mice are still able to produce IFN-I, mice deficient in IRF7 are
severely impaired in the production of IFN-I. Therefore, IRF7
has been assigned the master regulator of interferon.28,29
Although many nonimmune cells possess the molecular ele-
ments that may allow them to produce IFN-I, the extent to which
they participate in an effective IFN-I response during viral
infection is not clear. In this report, we analyzed the contribution of
hematopoietic versus nonhematopoietic cells in the production of
IFN-I. As expression of IRF7 is essential for production of IFN-I,
we used BM chimeras generated from irf7/ and wild-type (WT)
mice. We found that during systemic viral infections, IFN-I from a
BM-derived source was essential for the control of virus replication
and inhibition of viral spread to peripheral organs. In addition,
hematopoietic cell–derived IFN-I controlled disease onset and the
extent of pathology.
Methods
Mice and viruses
Vesicular stomatitis virus, Indiana strain (VSV-IND, Mudd-Summers
isolate) was originally obtained from Prof D. Kolakofsky (University of
Geneva, Geneva, Switzerland). Viruses were propagated on BHK-21
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cells at a multiplicity of infection (MOI) of 0.01 and plaqued on Vero
cells. Lymphocytic choriomeningitis virus (LCMV) strain WE was
originally obtained from F. Lehmann-Grube (Heinrich Pette Institute,
Hamburg, Germany) and was propagated in L929 cells. Virus titers were
measured using a focus-forming assay as previously described.30 Mouse
hepatitis virus (MHV) A59 was generated from a molecularly cloned
cDNA31 based on the Albany strain of MHV A59 and propagated on
L929 cells. Herpes simplex virus (HSV) was used as described.29 For
generation of BM chimeras, mice were lethally irradiated (1050 rad) on
day 1. On day 0, 8  106 BM cells, generated by flushing the femur
and tibia of naive WT (C57BL/6) mice or irf7/ mice, were injected
intravenously. Irf7/ mice, RIP-GP mice, and green fluorescent protein
(GFP) transgenic mice were maintained on the C57BL/6 genetic
background. All experiments were performed in single ventilated cages.
Animal experiments were carried out with authorization of the Veteri-
na¨ramt of the Kanton Zurich in accordance with the Swiss law for
animal protection and according to institutional guidelines at the
Ontario Cancer Institute.
In vitro treatment with IFN-
The fibroblast cell line MC57 was seeded in 24-well plates. After 24 hours,
cells were treated with 1000, 100, and 10 units of IFN- (PBL Biomedical
Laboratories, Piscataway, NJ) and in parallel infected with VSV (MOI
0.001) or LCMV (MOI 0.001). After 6, 12, and 24 hours, virus in
supernatant was analyzed for infectious virus using focus-forming assay.
Depletion of natural killer cells and CD8 T cells
Natural killer (NK) cells were depleted using the commercially available
-asialo GM1 antibody (Wako Chemicals, Richmond, VA) according to the
manufacturer’s suggestions. CD8 T cells were depleted by intraperitoneal
or intravenous injection of a rat monoclonal antibody specific for mouse
CD8 (clone YTS169.4) on days3 and1 before infection.
mRNA gene profiling by quantitative RT-PCR
RNA extraction and production of cDNA was performed as described.32
Gene expression analysis of collagen and 18S RNA was performed using
kits from Applied Biosystems (Foster City, CA). For analysis, the expres-
sion levels of all target genes were normalized against 18S rRNA or GapDH
mRNA (Ct). Gene expression values were then calculated based on the
Ct method, using the mean of 3 untreated mice as a standard to which all
other samples were compared. Relative quantities (RQ) were determined
using the equation RQ  2ˆ  Ct.
IFN- enzyme-linked immunosorbent assay
IFN- enzyme-linked immunosorbent assay (ELISA) was performed according
to the manufacturer’s suggestions (Research Diagnostics, Concord, MA).
Histology
Histologic analysis was performed on snap-frozen tissue as described.32
Antibodies against mouse CD8 (clone YTS169.4), LCMV-NP (clone VL4),
and major histocompatibility complex (MHC) I (M1/42) were used.
Histology was developed using an alkaline phosphatase or a peroxidase
system. Pictures were made with an Olympus BX50 (San Diego, CA) and a
Photometrics (Pleasanton, CA) Coolsnap HQ2 camera using 200 magni-
fication (20 objective). Image Pro analyzer Software (Media Cybernetics,
Bethesda, MD) was used.
Fluorescence-activated cell sorting analysis
Tetramer production, surface and intracellular fluorescence-activated cell sorting
(FACS) staining was performed as described previously.32 In brief, cells were
stained for 15 minutes with tetramers at 37°C followed by incubation with the
antibodies anti-CD8, anti-CD69, anti-CTLA4, anti-CD62L, or anti-CD44 (BD
Bioscience, Franklin Lakes, NJ) or the antibodies anti–PD-1 or anti–IL-7R
(eBioscience, San Diego, CA). To measure intracellular IFN- production,
splenocytes were incubated with peptide for 6 hours at 37°C, for the last 5 hours
with 1 mg/L BrefeldinA(Sigma-Aldrich, St Louis, MO), then stained for CD8 at
4°C. After 30 minutes, cells were fixed, permeabilized, and then stained with
anti–IFN- antibody (BD Biosciences).
ALT measurement
Serum was used for alanine 2-oxoglutarate-aminotransferase (ALT) mea-
surements using a Hitachi 747 autoanalyzer (Tokyo, Japan).
Blood glucose
Blood glucose was measured using a glucometer (Bayer, Tarrytown, NY).
Statistical analysis
Data are expressed as mean plus or minus SEM. For statistical analysis a
Student t test, 1-way analysis of variance (ANOVA) or a 2-way ANOVA
(repeated measurements) with additional Bonferroni test was used to
determine significant differences.
Results
Systemic interferon is produced by hematopoietic cells
IRF7 is considered to be the master regulator of IFN-I. We
compared IFN- responses in irf7/ mice and control WT mice
infected with the cytopathic VSV or the noncytopathic LCMV,
which are well known to induce a strong systemic interferon
response. As previously described, we found that infection of mice
with VSV or LCMV led to strong IFN- production that was
dependent on IRF7 (Figure 1A,B).29,33 Increased IFN- correlated
with enhanced production of ifna4, ifnb1, but not ifnk in the spleen
(Figure 1C,D). In parallel, the interferon-induced genes irf7, usp18
and isg15 were up-regulated in response to viral infection in our
models (Figure 1E,F). To evaluate the contribution of hematopoi-
etic versus nonhematopoietic cells in production of systemic IFN-I,
we used BM chimeras where irf7/ BM was transferred into WT
mice and vice versa. BM development and reconstitution efficiency
was comparable between different sets of chimeras, suggesting that
development of BM cells was independent of IRF7 (Figure S1,
available on the Blood website; see the Supplemental Materials
link at the top of the online article). To analyze the contribution of
BM-derived cells in the production of systemic IFN-I, we infected
chimeric mice with VSV, LCMV, and HSV. We found that during
infection, in all 3 cases, systemic IFN-I was dependent on IRF7
expressed on BM-derived cells (Figure 1G-I).
Hematopoietic cell–derived interferon is essential for the
control of MHV and to limit hepatitis
We found that the induction of high concentrations of IFN-I is
dependent on BM-derived cells during systemic viral infections.
Therefore, we continued to analyze the influence of hematopoi-
etic cell–derived IFN-I on the control of viral replication and
disease outcome. Irf7/ mice, WT mice, and BM chimeric mice
were infected with the cytopathic MHV A59. Although it is
known that plasmacytoid dendritic cell-derived IFN-I is impor-
tant for MHV control,34 the possible contribution of small
amounts of nonhematopoietic cell–derived interferon in viral
control has not yet been analyzed. While irf7/ mice were
overwhelmed with MHV infection, transplantation of WT BM
restored the host’s capacity to control the virus (Figure 2A).
However, WT mice transplanted with IRF7-deficient BM were
unable to control the infection, because high viral titers in liver
and spleen were detected and virus was found also in other
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organs such as the lungs (Figure 2A). The lack of viral control in
these mice was similar to that observed in mice with a total
deficiency in IRF7, suggesting that IFN from hematopoietic
origin was essential for controlling MHV infection.
To analyze the effect of interferon derived from distinct sources on
MHV-induced hepatitis, we determined blood ALT levels. ALT levels
were elevated during MHV infection in mice with general IRF7
deficiency (Figure 2B).Although transplantation of WT BM into irf7/
mice prevented hepatitis, WT mice with irf7/ BM had severe
hepatitis, suggesting that liver damage in MHV-induced hepatitis can be
reduced only by IFN-I from hematopoietic origin (Figure 2B). Taken
together, our results show that only IFN- from hematopoietic origin
can control MHV infection and that nonhematopoietic cells are not able
to produce IFN- in sufficient amounts to prevent MHV-induced
pathology.
Replication of LCMV is inhibited by IFN-I produced by
hematopoietic cells
Because systemic replication of cytopathic MHV was controlled by
interferon derived from hematopoietic cells, we wanted to determine
whether this was also true for the noncytopathic virus LCMV. Consis-
tent with the MHV model, we found that in the absence of IRF7 in
BM-derived cells, LCMV spread into liver, lung, and kidney (Figure
Figure 1. Systemic interferon is produced by hematopoietic cells. (A) Irf7/ mice and WT mice were infected with VSV. IFN- serum levels are shown (n 2). (B) Irf7/ mice
and WT mice were infected with LCMV. IFN- serum levels are shown (n 2). (C) WT mice were infected with VSV. After 10 hours, IFNa4, IFNb, and IFNk transcript levels were
quantitated by RT-PCR (n 3). (D) WT mice were infected with LCMV. After 10 hours, IFNa4, IFNb, and IFNk transcript levels were assessed by RT-PCR (n 3). (E) WT mice were
infected with VSV.After 10 hours, IRF7, USP18, and ISG15 transcript levels were assessed in the spleen by RT-PCR (n 3). (F) WT mice were infected with LCMV.After 10 hours, IRF7,
USP18, and ISG15 transcript levels were assessed in the spleen by RT-PCR (n 3). (G-I) Bone marrow (BM) chimeras (WT-BM	WT, WT-BM	 irf7/, irf7/-BM	WT and
irf7/-BM	 irf7/ as described in “Methods”) were infected with VSV, n 3-4 (G), LCMV, n 4, (H), or HSV, n 5 (I). IFN-was measured in the serum.
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3A). Interestingly, we found that viral titers in the spleen were
independent of IRF7 (Figure 3A). Replication of LCMV in liver and
kidney was dependent on IRF7 expressed on BM-derived cells (Figure
3A). LCMV did not replicate in the lungs of WT mice. If such mice
were transplanted with WT BM, there was detectable viral replication
(Figure 3A), which suggests that there may be a form of innate
immunodeficiency in the lung after BM transplantation. Interferon
signaling can directly suppress virus replication due to induction of
molecules like RNAse L, Mx1, and protein kinase R.35,36 In addition,
interferons influence the T cells, B cells, and NK cells, which also might
contribute to the suppression of virus replication.32,37,38 To analyze if
activation of adaptive immune cells rather than a direct antiviral effect
was responsible for early LCMV suppression, we depleted Rag/mice
(lacking B and T cells) of NK cells and infected them with LCMV.
Figure 2. Hematopoietic-derived interferon is essential for the control of MHV and to limit hepatitis. WT mice, irf7/ mice, and BM chimeras (WT-BM 	 WT,
WT-BM 	 irf7/, irf7/-BM 	 WT and irf7/-BM 	 irf7/) were infected with 50 plaque-forming units (PFU) MHV intraperitoneally. (A) After 2 days, viral titers were
measured in the spleen, liver, lung, and blood (n  4-5). (B) ALT levels were measured in the serum (n  4-5).
Figure 3. Systemic replication of LCMV is inhibited by IFN-I produced by hematopoietic cells. (A) WT mice, irf7/ mice, and BM chimeras (WT-BM 	 WT,
WT-BM 	 irf7/, irf7/-BM 	 WT and irf7/-BM 	 irf7/) were infected with 200 PFU LCMV. After 4 days, viral titers were analyzed (n  4-5). (B) WT mice, WT mice
depleted of CD8 T cells and NK cells, and Rag/ mice depleted of NK cells were infected with 200 PFU LCMV-WE intravenously. Virus titers were analyzed in spleen liver,
lung, and kidney 3 days after infection. (C) MC57 cells were treated with different concentrations of IFN- and then infected with VSV or LCMV (MOI 0.001). After 6, 12, and
24 hours, infectious virus was analyzed in the supernatant.
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Rag/ mice showed a slightly reduced replication of LCMV
likely due to their splenic architecture.39 However, the interferon-
induced suppression of virus replication in peripheral organs
was not dependent on lymphocytes (Figure 3B). This suggests
that early inhibition of virus replication in vivo is due to a direct
antiviral effect. This was supported by in vitro data which
indeed showed that replication of both VSV and LCMV in
MC57 cells can be inhibited strongly by interferons (Figure 3C).
Hematopoietic cell–derived interferon influenced CD8 T-cell
expansion
We found that production of IFN-I by BM-derived cells reduces early
viral replication. Next, we wanted to examine the role of BM-derived
IFN-I in the adaptive immune response and the induction of virus-
induced immunopathology. To address this, we used the RIP-GP model.
RIP-GP mice transgenically express the glycoprotein of LCMV under
the rat insulin promoter. Infection with LCMV leads to activation of
LCMV-GP–specific CD8 T cells that recognize the LCMV-GP ex-
pressed on pancreatic -islet cells. This leads to the destruction of the
-islet cells and the induction of diabetes.40 Chimeras were generated
using BM from WT or irf7/mice, and after reconstitution, the animals
were infected with LCMV. The frequencies of virus-specific tet-gp33
CD8 T cells were not significantly different between RIP-GP mice
reconstituted with WT or irf7/ BM (Figure 4A). Expression of CD44,
CD62L, IL-7R, and PD-1 was not affected by systemic IFN-I (Figure
4B). Expression of CD69 and CTLA4 seemed to be slightly higher in
WT mice reconstituted with WT BM; however, the difference was not
statistically significant under the settings of our experiment (Figure 4B).
The expansion of CD8 T cells was significantly reduced in mice
lacking IRF7 in BM-derived cells (Figure 4C). Generation of IL7R
Figure 4. Hematopoietic cell–derived interferon influ-
enced CD8 T-cell expansion. Bone marrow chimeras
(WT-BM 	 RIP-GP, irf7/-BM 	 RIP-GP) were infected
with 200 PFU LCMV-WE. (A) Frequencies of LCMV-
specific CD8 T cells were analyzed on day 8 in the
blood (n  4-5). (B) Splenic CD8 T cells were analyzed
for tet-gp33 cells (LCMV-specific cells) and phenotype.
One representative dot plot is shown. Cells are gated on
CD8 T cells. (C) Expansion of total CD8 T cells was
analyzed in the blood using tetramers (n  4-5). (D) Ex-
pression of IL-7R on tet-gp33 positive cells was ana-
lyzed in blood-derived CD8 T cells. One of 4 or 5 repre-
sentative stainings is shown. (E) On day 30, pancreatic
islet cells were analyzed for replication of LCMV within
the islets. One of 3 representative slides is shown.
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memory CD8 T cells was also significantly reduced in mice with
IRF7-deficient BM, correlating with persistence of antigen
(Figure 4D,E). Thus, we found reduced expansion of total CD8
T cells when IRF7 was deficient in BM-derived cells, which was
probably due to a lack of interferon signaling directly in CD8
T cells.37,41 Therefore, in response to LCMV challenge, BM-
derived IFN-I influenced CD8 T-cell expansion, the memory
T-cell population, and consequently virus persistence.
Hematopoietic cell–derived interferon influenced type 1
diabetes
Recently, it was shown that induction of IFN-I by pathogen
recognition receptor ligands can enhance antigen presentation and
production of chemokines in the target organ.42,43 We, therefore,
attempted to address the role of IRF7 in these processes. Indeed, we
found that poly(I:C)–induced up-regulation of MHC I was reduced
in irf7/ mice (Figure 5A). In keeping with the described
interferon-dependent chemokine production, minimal CD8 T-cell
infiltration was observed 8 days after infection in RIP-GP mice
receiving irf7/ BM (Figure 5B). Infection with LCMV led to
up-regulation of MHC I in WT mice receiving WT BM and this
was reduced in WT mice receiving irf7/ BM (Figure 5B). It is
likely that IFN-I acts on the -islet cells in synergy with other
cytokines including TNF- and IFN-.44,45 Lack of IRF on
BM-derived cells reduced CD8 T cell–dependent cytotoxicity in
pancreatic islets and, therefore, was essential for induction of
autoimmune diabetes in this mouse model (Figure 5C).
Discussion
Several cell types are potentially able to produce IFN-I.6-13 We
found here that IFN-I produced by hematopoietic cells was
essential to control systemic viral infections. Mice lacking IRF7 on
BM-derived cells were unable to control and limit MHV infection
and viral-induced hepatitis. The lack of IRF7 on hematopoietic
cells resulted in virus dissemination to nonlymphoid organs. This
enhanced and widespread infection correlated with a subsequent
reduction of T-cell frequencies, especially at later stages of viral
disease. Furthermore, systemically produced IFN-I directly influ-
enced infiltration of autoreactive CD8 T cells into pancreatic
-islet cells. In our mouse model, the lack of IFN-I therefore
prevented the induction of autoimmune diabetes. This is in
accordance with a general role of interferons in autoimmune
diseases.46 In humans, diseases like systemic lupus erythemato-
ses,47-50 type I diabetes,51,52 and psoriasis53 are typically linked with
IFN-I. Those diseases require local action of IFN-I. From our data,
we would suggest that not only the local production of IFN-I,53 but
also a strong systemic induction of IFN-I can trigger such
autoimmune diseases. Therefore, a systemic infection with vi-
rus could potentially trigger autoimmune diabetes, without any
cross-reactivity or any replication of the virus in the pancreatic
-islet cells.54
The contribution of IFN-I in the induction of diabetes has also
been examined in other mouse models.42,55,56 Infection of mice with
coxsackievirus led to the induction of diabetes when IFN-I
signaling was abrogated in -islet cells.57 Although this model
appears contradictory to our RIP-GP model, it is consistent with
our data as defective interferon response in -islet cells led to direct
replication of coxsackievirus in the target organ. Therefore, the
-islet cells become targets of the virus cytotoxicity and the
immune response against the virus.57 These data are in agreement
with our MHV data, where the lack of systemic IFN-I led to
enhanced replication of MHV in the liver, which enhances virus
cytotoxicity in hepatocytes.
The role of systemic interferon in multiple sclerosis is not well
understood. Although multiple sclerosis is certainly an autoim-
mune disease involving the innate and the adaptive immune
Figure 5. Hematopoietic cell–derived interferon influenced autoimmune diabe-
tes. (A) WT and irf7/ mice were treated with 500 
g poly(I:C) intravenously. After
24 hours, MHC I expression was analyzed in the pancreas. One of 3 representative
stainings is shown. (B) BM chimeras (WT-BM 	 RIP-GP, irf7/-BM 	 RIP-GP) were
infected with 200 PFU LCMV-WE. On day 8, pancreatic -islets were analyzed for
expression of MHC I and infiltration of CD8 T cells. One of 3 representative stainings
is shown. (C) BM chimeras (WT-BM 	 RIP-GP, irf7/-BM 	 RIP-GP) were infected
with 200 PFU LCMV-WE. Blood glucose levels were analyzed in the blood (n  4-5).
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system, interferons are beneficial for the outcome of disease.58 This
was first shown by local treatment with IFN-I,59 but was also
demonstrated with the systemic action of IFN-I.60,61 This would
suggest that although neurons can produce IFN-I,19 systemic
interferon can influence relapses of multiple sclerosis. This role of
systemic interferon could theoretically be explained by enhanced
replication of virus in the central nervous system. Although there is
a some evidence of lack of virus control in multiple sclerosis
patients,62,63 the link between systemic IFN-I and multiple sclerosis
remains mostly unexplained.
The role of systemically induced interferon in human infections
is not well defined. First, the route of infection is usually not
intravenously. Therefore, local replication in endothelial cells or
lymph nodes might induce IFN-I before the virus spreads into the
blood. Interestingly, it was shown that in the severe acute respira-
tory syndrome (SARS) coronavirus, there was no induction of
interferon in several cell types.64,65 This could suggest that there
may be specialized interferon-producing cells during infection.34 In
fact, treatment with interferon can prevent SARS.66 The human
pathogenic hepatitis C virus can suppress the production of IFN-I
in hepatocytes.67 This could mean that lack of a strong systemic
interferon response leads to persistence of virus in the liver.68 In
addition, during this type of infection, systemic treatment with
IFN-I can inhibit replication of virus in hepatocytes.69,70 Notably,
the role of systemic interferon is unique during HIV infection
where there is little beneficial effect of IFN-I treatment.71 Curi-
ously, recent evidence suggests that overactivation of TLR signal-
ing leads to faster progression of AIDS.72
In summary, although a great variety of cell types are able to
produce IFN-I, hematopoietic cell–derived IFN-I is essential to
control systemic viral infection. Along with its strong antiviral
effects, hematopoietic cell–derived IFN-I influences the progres-
sion of diabetes induced in our LCMV model. These data suggest
that a systemic rather than a local treatment (depletion or addition)
of IFN-I is required to influence interferon-dependent diseases.
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